Yun Gong
Executive Director of Strategic Partnerships & General Manager of Platform Innorna
Seminars
Wednesday 22nd July 2026
Engineering Targeted mRNA‑LNPs to Enable In Vivo Immunotherapy for Autoimmune Diseases
2:00 pm
- NHP data demonstrating the potential of targeted mRNA‑LNPs to enable in vivo immunotherapy for autoimmune disease models
- Robust B‑cell depletion across peripheral blood, spleen, and lymphoid tissues using a proprietary targeted LNP delivery platform
- Evidence of immune‑reset biology with emerging safety and tolerability supporting continued pre-clinical development
